In rare move, Gilead gives up 'orphan' status for experimental coronavirus drug
Gilead has asked the Food and Drug Administration to rescind a special regulatory status for its experimental coronavirus drug, but not before stirring up a controversy that had critics accusing the company of manipulating a law designed to spur research into therapies for rare diseases.